18 results
424B5
KROS
Keros Therapeutics Inc
4 Jan 24
Prospectus supplement for primary offering
4:02pm
is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective Investors in Hong
424B5
KROS
Keros Therapeutics Inc
3 Jan 24
Prospectus supplement for primary offering
4:04pm
supplement is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective
DEF 14A
41w3sm imizwzsnh
19 Apr 21
Definitive proxy
4:15pm
10-K
3cd3qeaua7nw2hy2uv9
25 Mar 21
Annual report
8:23am
424B4
zcc6 pr3ej
13 Nov 20
Prospectus supplement with pricing info
4:02pm
DRS
46t8zy dl
3 Nov 20
Draft registration statement
12:00am
8-K
EX-99.1
h1vjj usuk
4 Aug 20
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
8:32am
424B4
jjtv eo4nk5vtm5
8 Apr 20
Prospectus supplement with pricing info
4:58pm
S-1
y3raxh eq
16 Mar 20
IPO registration
4:57pm
DRS/A
xs5xxqdsazc207xnepn
27 Feb 20
Draft registration statement (amended)
12:00am
DRS
jiwkf pyjr0
21 Jan 20
Draft registration statement
12:00am
- Prev
- 1
- Next